• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Forum Infect Dis . Predicting COVID 19-Associated Pulmonary Aspergillosis Risk in Low- and Middle-Income Countries: A Matched Case-Control Stu

tetano

Editor, Senior Moderator
Open Forum Infect Dis


. 2024 Jul 23;11(7):ofae406.
doi: 10.1093/ofid/ofae406. eCollection 2024 Jul. Predicting COVID 19-Associated Pulmonary Aspergillosis Risk in Low- and Middle-Income Countries: A Matched Case-Control Study

Merlin Moni[SUP] 1 [/SUP], Dipu T Sathyapalan[SUP] 1 [/SUP], Fabia Edathadathil[SUP] 2 [/SUP], M Abdul Razak[SUP] 1 [/SUP], Sivapriya G Nair[SUP] 1 [/SUP], Chithira V Nair[SUP] 1 [/SUP], Swathy S Samban[SUP] 1 [/SUP], Preetha Prasanna[SUP] 3 [/SUP], Kiran G Kulirankal[SUP] 1 [/SUP], Shyam Sundar Purushothaman[SUP] 4 [/SUP], Georg Gutjahr[SUP] 5 [/SUP], Jiang Ying[SUP] 6 [/SUP], Teny M John[SUP] 6 [/SUP]



Affiliations
Abstract

Background: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a life-threatening fungal infection. Studies focusing on CAPA in low- and middle-income countries are limited.
Methods: This retrospective matched case-control study was conducted at a tertiary care center in South India. Cases of CAPA were classified using the 2020 European Confederation of Medical Mycology/International Society for Human and Animal Mycology consensus criteria. A total of 95 cases were matched 1:1 with COVID-19 patients without CAPA. Matching was done based on age and period of admission. Inverse probability weighting was used to account for imbalances in COVID-19 severity and intensive care unit (ICU) admission. Data on demographics, clinical details, microbiologic and radiologic data, and treatment outcomes were collected. A predictive score for CAPA was developed from baseline risk factors.
Results: The predictive score identified lymphopenia, European Organisation for Research and Treatment of Cancer risk factors, and broad-spectrum antibiotic use as the main risk factors for CAPA. Positivity for bacterial pathogens in blood or bronchoalveolar lavage samples reduced the risk of CAPA. The predictive model performed well in cross-validation, with an area under the curve value of 82%. CAPA diagnosis significantly increased mortality and shift to ICU.
Conclusions: The predictive model derived from the current study offers a valuable tool for clinicians, especially in high-endemic low- and middle-income countries, for the early identification and treatment of CAPA. With further validation, this risk score could improve patient outcomes.

Keywords: COVID-19; aspergillosis; galactomannan; invasive fungal infection; secondary bacterial infections.

 
Back
Top Bottom